Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its wholly-owned subsidiary, SystImmune, recently received a $250 million milestone payment from Bristol-Myers Squibb (BMY). According to the collaboration agreement, the company is also eligible for up to an additional $250 million in near-term contingent payments, as well as potential payments of up to $7.1 billion upon achieving specific development, regulatory, and sales milestones. The milestone payments outlined in the agreement are subject to certain conditions, and the final payment amounts remain uncertain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments